Cadent Therapeutics is rapidly advancing a pipeline of novel allosteric modulators of ion channels – taking a well-established pharmaceutical approach and stepping out into new territory. SK channels and NMDA receptors are ion channels that are critical for modulating the strength, timing, and integration of communication between and within neurons and neuronal networks in the central nervous system. But there are no approved drugs that are selective allosteric modulators of these ion channels. Cadent’s first-of-its-kind approach has the potential to bring harmony back to neuronal rhythms, effectively “re-wiring” the brain to treat movement and cognitive disorders.
To address movement disorders with limited or no treatment options, such as spinocerebellar ataxia and essential tremor, we are developing positive allosteric modulators (PAM) of SK channels (calcium-sensitive potassium ion channels). SK channels are expressed throughout the central nervous system and are responsible for regulating the amount of potassium that enters a cell and affect the inherent excitability of neurons and communication between synapses. Through SK channel modulation, we hope to control the firing rate (amount of times a neuron fires at any given time) and the firing pattern (allocation of firing over time), thereby restoring balance to the brain’s rhythms.
Among a number of psychiatric conditions leading to cognitive disorders, patients with schizophrenia and treatment resistant depression represent significant unmet need. Our approach aims to modulate the N-methyl-D-asparate receptor (NMDAr), one of a group of glutamate receptors responsible for efficient synaptic communication, which is important for controlling synaptic plasticity and memory function. Disruptions in the NMDAr signaling pathway, have been documented in a number of neuropsychiatric conditions including schizophrenia, mood disorders, Alzheimer’s disease, and other neuro-developmental disorders.
To address cognitive impairment associated with schizophrenia (CIAS), we aim to positively modulate NMDAr to reverse NMDAr hypofunction and restore cognitive balance. NMDAr hypofunction results in impairment of the brain’s ability to process and differentiate variations and novelty in stimuli, including different types of sounds. Proper functioning of NMDAr in the brain is critical for learning, memory and the ability to form new neuronal connections (neuroplasticity). In people with schizophrenia NMDAr dysregulation has been implicated in cognitive impairment. In experiments conducted on healthy subjects using NMDAr antagonists, Data have shown that impairment in one measure of sensory and cognitive processing, called Mismatch negativity (MMN), is correlated with cognitive deficit, negative symptoms, and deficit in global function, similar to that observed in patients with schizophrenia. Treatment with our NMDAr PAM preclinical studies has demonstrated to restore MMN in a model of NMDAr hypofunction.
Meet Our Senior Leadership Team
We have assembled a world-class team that is committed to bringing new, life-changing medicines to the people who need them most.
Chief Executive Officer
Jodie Morrison is the Chief Executive Officer of Cadent Therapeutics and is a member of Cadent’s Board of Directors. Ms. Morrison most recently served as interim Chief Executive Officer at Keryx Biopharmaceuticals, Inc. Previously she served as President and Chief Executive Officer of Tokai Pharmaceuticals, Inc…
President and Head of Research and Development
Michael Curtis is the President of Cadent Therapeutics and is a member of Cadent’s Board of Directors with over 25 years of experience in bringing novel treatments to patients. Prior to joining Cadent, he was Senior Vice President of Product Development and Regulatory Affairs at Catabasis Pharmaceuticals…
Chief Scientific Officer
Tim Piser is the Chief Scientific Officer of Cadent Therapeutics and has passionately pursued the discovery and development of neuroscience therapeutics for almost two decades in big pharma and in biotech, most notably at AstraZeneca and FORUM Pharmaceuticals. There, he led neuropharmacology…
Vice President of Product Development
Gregg Keaney is the Vice President of Product Development at Cadent Therapeutics and leads CMC (Chemistry, Manufacturing, and Controls) development, Phase 1 clinical operations, and a broad range of interdisciplinary portfolio management activities. At Ataxion Therapeutics, Gregg led…